Speaker Profile

MBA, CEO, American BioOptics

Mr. Eric Benson is proud to introduce ABO’s InPoint™ System. A fast, convenient and personalized cancer risk stratification device that addresses at-risk populations, across several cancer screening programs, in order to identify high-risk patients at an early stage needing further care. Mr. Benson directs the Company’s strategic initiatives and financial well-being, while overseeing its legal and quality obligations, and its development, regulatory and manufacturing practices. Prior to leading ABO, Mr. Benson provided corporate development, finance and product planning support to a number of emerging medical product companies. Lead new product forecasting and strategy for at Astellas Pharma where he directed commercial analysis on both pipeline and in-line opportunities for BD&L and R&D teams. And prior he conducted Healthcare M&A investment banking at Dresner Partners, and managed R&D at Intergrated Genomics and Aastrom Biosciences.

Clinical Dx Showcase: American BioOptics
American BioOptics is revolutionizing cancer screening with the InPoint™ System, the first POC optical biopsy device to identify high-risk patients.

InPoint™ System: An Optical Biopsy Device For Cancer Risk Stratification
The InPoint™ System – a first-line, multi-indication cancer risk assessment platform – improves the screening process and patient outcomes by 1) increasing at-risk patient compliance, and 2) providing a cost-effective method to identify high-risk patients early, and in need of follow-up care.

Get Exclusive Access to the Top PMWC Talks

To receive the most comprehensive news and updates from the field of precision medicine, subscribe to the newsletter here.

Bonus for suscribing, you will get the access code for the top 3 talk videos from January's Precision Medicine World Conference.

You have successfully subscribed, you can access the talks here.